Ovulatory Disorders — MCQs
Which of the following is the most reliable test for ovulation?
Which serum level is increased in premature ovarian failure?
A female patient presents with hirsutism, amenorrhea, and obesity. What is the most likely diagnosis?
A lady presents with amenorrhea and galactorrhea. What is the most likely cause?
During the evaluation of secondary amenorrhea in a 24-year-old woman, hyperprolactinemia is diagnosed. Which of the following conditions could cause increased circulating prolactin concentrations and amenorrhea in this patient?
A 27-year-old female presented to OPD of infertility clinic. She was prescribed bromocriptine. What could be the possible reason?
A major causal factor in some cases of hypogonadism is:
Which of the following statements about clomiphene citrate is true?
Spinnbarkeit is maximum shown at which phase?
Therapeutic options for a 30 year old woman suffering from severe pain due to endometriosis are the following except:
Ovulatory Disorders Indian Medical PG Practice Questions and MCQs
Question 1: Which of the following is the most reliable test for ovulation?
- A. Basal body temperature
- B. Vaginal cytology
- C. Serum Progesterone level (Correct Answer)
- D. Endometrial biopsy
Explanation: ***Serum Progesterone level*** - A **serum progesterone level** measured approximately 7 days after the presumed ovulation (mid-luteal phase) is the most reliable biochemical indicator of ovulation. A level of **≥3 ng/mL** confirms ovulation. - The rise in progesterone is due to its production by the **corpus luteum** formed after the rupture of the mature follicle during ovulation. *Basal body temperature* - **Basal body temperature (BBT)** charting shows a slight increase (0.5-1.0°C) after ovulation due to the thermogenic effect of progesterone. However, this rise is **retrospective** and only indicates that ovulation has already occurred. - BBT can be influenced by various factors, such as illness, stress, and sleep patterns, making it **less precise** than direct hormonal measurement. *Vaginal cytology* - **Vaginal cytology** can show changes in epithelial cell morphology (e.g., increased cornified cells) during the periovulatory period due to estrogen influence. - These changes are **indicative of estrogen activity** and cervical mucus quality, but they do not directly confirm the rupture of the follicle or the release of an egg. *Endometrial biopsy* - An **endometrial biopsy** can reveal secretory changes in the endometrium characteristic of the luteal phase, which are a result of progesterone production after ovulation. - However, this is an **invasive procedure** and not a practical or primary test used solely for confirming ovulation.
Question 2: Which serum level is increased in premature ovarian failure?
- A. Serum Inhibin
- B. Serum FSH (Correct Answer)
- C. Serum Estradiol
- D. Serum Progesterone
Explanation: ***Serum FSH*** - In **premature ovarian failure**, the ovaries fail to produce sufficient estrogen and inhibin, leading to a loss of negative feedback on the pituitary gland. - This lack of negative feedback results in continuously **elevated levels of FSH** as the pituitary tries to stimulate the non-responsive ovaries. *Serum Inhibin* - **Inhibin** is a hormone produced by ovarian granulosa cells, which normally inhibits FSH secretion. - In premature ovarian failure, due to ovarian dysfunction, **inhibin levels are typically decreased**, not increased. *Serum Estradiol* - **Estradiol** is the primary estrogen produced by the ovaries. - In premature ovarian failure, the ovaries are failing, resulting in **decreased production of estrogen/estradiol**. *Serum Progesterone* - **Progesterone** is primarily produced after ovulation by the corpus luteum. - In premature ovarian failure, ovulation is impaired or absent, leading to **low or undetectable progesterone levels**.
Question 3: A female patient presents with hirsutism, amenorrhea, and obesity. What is the most likely diagnosis?
- A. Androgen-secreting ovarian tumor
- B. Congenital adrenal hyperplasia
- C. Cushing's syndrome
- D. Polycystic Ovary Syndrome (PCOS) (Correct Answer)
Explanation: ***Polycystic Ovary Syndrome (PCOS)*** - **Hirsutism**, **amenorrhea** (or oligomenorrhea), and **obesity** are classic clinical features of PCOS, reflecting hyperandrogenism and insulin resistance [2]. - PCOS is a diagnosis of exclusion and involves chronic anovulation and polycystic ovaries on ultrasound [3], though these are not explicitly mentioned, the constellation of symptoms strongly points to it. *Androgen-secreting ovarian tumor* - While it can cause **hirsutism** and **amenorrhea**, the onset is typically **rapid** and severe, with very high androgen levels, and obesity is not a primary feature. - Ovarian tumors are generally less common than PCOS and may present with a palpable mass or specific imaging findings. *Congenital adrenal hyperplasia* - This genetic condition often presents in childhood or adolescence with varying degrees of **virilization** and menstrual irregularities due to enzyme deficiencies in cortisol synthesis [1]. - While it causes **hirsutism** and potentially **amenorrhea**, obesity is not a direct consequence, and the patient's age of presentation and specific symptom pattern are less typical for adult-onset CAH in this context. *Cushing's syndrome* - Characterized by **central obesity**, **moon facies**, **buffalo hump**, **striae**, and proximal muscle weakness due to chronic glucocorticoid excess. - Although it can cause **menstrual irregularities** and mild **hirsutism** [2], the overall clinical picture including the absence of other specific Cushingoid features makes it less likely than PCOS.
Question 4: A lady presents with amenorrhea and galactorrhea. What is the most likely cause?
- A. None of the options
- B. Pituitary adenoma (Correct Answer)
- C. Adrenal hyperplasia
- D. 7α-hydroxylase deficiency
Explanation: ### Pituitary adenoma - A **prolactin-secreting pituitary adenoma** (prolactinoma) is the most common cause of sustained **hyperprolactinemia**, leading to both **amenorrhea** and **galactorrhea** [1]. - **Elevated prolactin levels** inhibit gonadotropin-releasing hormone (GnRH) pulsatility, leading to reduced LH and FSH, causing anovulation and amenorrhea, alongside direct stimulation of breast tissue for galactorrhea [1], [2]. ### *None of the options* - This option is incorrect as **pituitary adenoma** is a highly plausible cause for the presented symptoms. - The combination of **amenorrhea** and **galactorrhea** is a classic presentation of hyperprolactinemia, often due to a pituitary adenoma [1]. ### *Adrenal hyperplasia* - **Adrenal hyperplasia** typically involves overproduction of androgens or cortisol, leading to symptoms like **hirsutism**, **virilization**, or **Cushing's syndrome**, rather than galactorrhea [3]. - While it can cause menstrual irregularities, it does not directly cause **galactorrhea**, which is primarily linked to prolactin excess [1], [3]. ### *7α-hydroxylase deficiency* - **7α-hydroxylase deficiency** is a rare genetic disorder affecting **bile acid synthesis**, not directly related to reproductive hormones or prolactin regulation. - Its clinical manifestations are primarily related to **liver disease** due to abnormal bile acid metabolism and would not present with amenorrhea and galactorrhea.
Question 5: During the evaluation of secondary amenorrhea in a 24-year-old woman, hyperprolactinemia is diagnosed. Which of the following conditions could cause increased circulating prolactin concentrations and amenorrhea in this patient?
- A. Stress
- B. Hypothyroidism (Correct Answer)
- C. Eating disorders
- D. Adrenal disorders
Explanation: ***Hypothyroidism*** - **Primary hypothyroidism** leads to increased **TRH** (thyrotropin-releasing hormone) from the hypothalamus. TRH stimulates both **TSH** (thyroid-stimulating hormone) and **prolactin** release from the pituitary, causing hyperprolactinemia [1]. - Elevated prolactin then inhibits **GnRH** (gonadotropin-releasing hormone) secretion, leading to reduced LH and FSH, which results in **anovulation** and **amenorrhea**. *Stress* - While acute stress can transiently increase **prolactin levels**, severe and chronic stress typically leads to **hypogonadism** via effects on GnRH, but not usually hyperprolactinemia sufficient to cause prolonged amenorrhea. - Stress-induced amenorrhea is more often related to **functional hypothalamic amenorrhea**, characterized by low or normal prolactin, and is primarily a disorder of GnRH pulse generation. *Eating disorders* - Conditions like **anorexia nervosa** or **bulimia nervosa** can cause amenorrhea due to **low body weight** and nutritional deficiencies, leading to **hypothalamic dysfunction** and low estrogen levels [3]. - These disorders typically result in **hypogonadotropic hypogonadism** (low LH, FSH, and estrogen) rather than **hyperprolactinemia**. *Adrenal disorders* - Adrenal disorders like **Cushing's syndrome** or **adrenal insufficiency** can cause menstrual irregularities and amenorrhea, but they are not typically associated with **hyperprolactinemia** [2]. - **Congenital adrenal hyperplasia (CAH)** can cause androgen excess and menstrual irregularities, but prolactin levels are usually normal.
Question 6: A 27-year-old female presented to OPD of infertility clinic. She was prescribed bromocriptine. What could be the possible reason?
- A. Hypogonadotropic hypogonadism
- B. Hyperprolactinemia (Correct Answer)
- C. Pelvic inflammatory disease
- D. Polycystic ovary syndrome
Explanation: ***Hyperprolactinemia*** - **Bromocriptine** is a **dopamine agonist** that effectively reduces elevated prolactin levels, which can cause anovulation and infertility. - High prolactin can inhibit GnRH release leading to impaired follicular development and **infertility**. *Hypogonadotropic hypogonadism* - This condition involves low levels of **gonadotropins (LH and FSH)**, leading to reduced ovarian function. - Treatment typically involves **gonadotropin therapy** (e.g., FSH and LH agonists), not bromocriptine. *Pelvic inflammatory disease* - PID is an infection of the female reproductive organs, often leading to **fallopian tube blockage** and infertility. - Treatment involves **antibiotics** to clear the infection and often surgical correction, not bromocriptine. *Polycystic ovary syndrome* - PCOS is a hormonal disorder characterized by **anovulation**, hyperandrogenism, and polycystic ovaries. - Management often includes **lifestyle modifications**, metformin, clomiphene citrate, or letrozole, not primarily bromocriptine, unless there is co-existing hyperprolactinemia.
Question 7: A major causal factor in some cases of hypogonadism is:
- A. Reduced secretion of gonadotropin-releasing hormone (GnRH) (Correct Answer)
- B. Excess secretion of testicular activin by Sertoli cells
- C. Hypersecretion of pituitary LH and FSH as the result of increased GnRH
- D. Failure of the hypothalamus to respond to testosterone
Explanation: ***Reduced secretion of gonadotropin-releasing hormone (GnRH)*** - **Hypogonadotropic hypogonadism** is characterized by low levels of LH and FSH due to inadequate GnRH secretion from the hypothalamus, leading to decreased testosterone production. - This can be caused by various factors, including genetic conditions, hypothalamic tumors, or functional suppression from stress or severe illness. *Excess secretion of testicular activin by Sertoli cells* - **Activin** promotes FSH synthesis and secretion from the pituitary but is not a primary cause of hypogonadism. - While disruptions in activin/inhibin balance can affect spermatogenesis, it doesn't directly cause a systemic hypogonadal state through its direct effect on GnRH or gonadal function. *Hypersecretion of pituitary LH and FSH as the result of increased GnRH* - **Hypersecretion of LH and FSH** in response to increased GnRH would lead to **hypergonadism**, or at least eugonadism, not hypogonadism. - This scenario would stimulate excessive testosterone production, the opposite of hypogonadism. *Failure of the hypothalamus to respond to testosterone* - The hypothalamus, as well as the pituitary, are sensitive to **negative feedback from testosterone** to regulate GnRH and gonadotropin release. - A failure to respond to testosterone would typically lead to **increased GnRH and gonadotropin secretion** (as the feedback loop is broken), resulting in higher testosterone levels, which contradicts hypogonadism.
Question 8: Which of the following statements about clomiphene citrate is true?
- A. Enclomiphene has antiestrogenic effects. (Correct Answer)
- B. The risk of multiple pregnancies is less than 1%.
- C. It is contraindicated in male hypogonadism.
- D. The chance of pregnancy is modestly increased compared to placebo.
Explanation: ***Enclomiphene has antiestrogenic effects.*** - Clomiphene citrate is a racemic mixture of two stereoisomers, **enclomiphene** (trans-isomer) and **zuclomiphene** (cis-isomer). - **Enclomiphene** is the more potent antiestrogenic isomer, which blocks estrogen receptors in the hypothalamus and pituitary, leading to increased **gonadotropin-releasing hormone (GnRH)** secretion and subsequent **follicle-stimulating hormone (FSH)** and **luteinizing hormone (LH)** release. - This mechanism is responsible for its effectiveness in inducing ovulation. *The chance of pregnancy is modestly increased compared to placebo.* - This is **incorrect** - Clomiphene citrate **significantly** increases the chances of ovulation and pregnancy in anovulatory women, representing much more than a modest increase. - Studies show substantial improvement in ovulation rates (70-80%) and live birth rates (30-40%) with clomiphene compared to placebo in women with anovulatory infertility. *The risk of multiple pregnancies is less than 1%.* - This is **incorrect** - The risk of multiple pregnancies with clomiphene citrate is actually **5-10%**, primarily twins (5-8%), with less than 1% for triplets or higher-order multiples. - This represents a significant increase compared to spontaneous conception rates (~1-2% twins naturally). *It is contraindicated in male hypogonadism.* - This is **incorrect** - Clomiphene citrate is actually used **off-label** in men with **hypogonadism** to stimulate endogenous testosterone production. - In men, it works by blocking estrogen receptors at the hypothalamic-pituitary level, leading to increased GnRH, LH, and FSH secretion, which stimulates **Leydig cells** to produce testosterone and **Sertoli cells** to support spermatogenesis.
Question 9: Spinnbarkeit is maximum shown at which phase?
- A. Menstrual phase
- B. Ovulatory (Correct Answer)
- C. Post ovulatory
- D. Follicular phase
Explanation: ***Ovulatory*** - **Spinnbarkeit** refers to the stringy, stretchy quality of cervical mucus, which is maximal during the ovulatory phase due to high **estrogen levels**. - This highly elastic mucus facilitates **sperm transport** to the uterus and fallopian tubes for fertilization. *Menstrual phase* - During the menstrual phase, **cervical mucus** is typically minimal and sticky, making it unfavorable for sperm survival. - This phase is characterized by low estrogen and progesterone levels, leading to the **shedding of the uterine lining**. *Post ovulatory* - After ovulation, under the influence of **progesterone**, cervical mucus becomes thick, sticky, and opaque, decreasing **spinnbarkeit**. - This change in mucus consistency forms a **barrier to sperm penetration** into the uterus. *Follicular phase* - In the early follicular phase, **estrogen levels** are low, resulting in thick, scanty, and opaque cervical mucus with low **spinnbarkeit**. - As the follicular phase progresses and estrogen levels rise, the mucus gradually becomes more **watery and elastic**, but it doesn't reach its peak stretchiness until ovulation.
Question 10: Therapeutic options for a 30 year old woman suffering from severe pain due to endometriosis are the following except:
- A. Mirena
- B. Letrozole
- C. Sildenafil (Correct Answer)
- D. Oral contraceptives
Explanation: ***Sildenafil*** - **Sildenafil** is a **vasodilator** primarily used for **erectile dysfunction** and **pulmonary hypertension**. - It has no established role in the **endocrine** or **anti-inflammatory** management required for endometriosis pain. *Mirena* - **Mirena** (levonorgestrel-releasing intrauterine system) is an effective treatment for endometriosis pain because it releases **progestin**, which **suppresses endometrial growth** and inflammation. - It helps reduce both **dysmenorrhea** and **chronic pelvic pain** associated with endometriosis. *Letrozole* - **Letrozole** is an **aromatase inhibitor** that reduces **estrogen synthesis**, which is crucial because endometriosis is an **estrogen-dependent** condition. - By lowering estrogen levels, it can significantly **reduce pain** and the progression of endometrial implants. *Oral contraceptives* - **Combined oral contraceptives (COCs)** are a common and effective first-line treatment for endometriosis pain, as they create a **pseudo-pregnancy state** and **suppress ovulation**. - This suppression leads to a reduction in **estrogen-driven endometrial growth** and subsequent pain.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free